EUS-Guided Optoelectronic Microprobe for Accurate Pancreatic Neoplasia Diagnosis

EUS引导光电微探针精准诊断胰腺肿瘤

• 批准号: 8822561
• 负责人: Mary-Ann Mycek
• 金额: $ 23.33万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-29 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8822561
• 关键词: Algorithms; Architecture; Aspirate substance; Biomedical Engineering; Cancer Detection; Cancer Patient; Cells; Cellularity; Classification; Clinical; Clinical Data; Clinical Trials; Detection; Development; Devices; Diagnosis; Diagnostic; Disease; Early Diagnosis; Early identification; Electrical Engineering; Endoscopy; Engineering; Environment; Excision; Feasibility Studies; Fine needle aspiration biopsy; Goals; Gold; Human; Internal Medicine; Malignant Neoplasms; Malignant neoplasm of pancreas; Measures; Methods; Michigan; Microfabrication; Needles; Operative Surgical Procedures; Optics; Outcome; Pancreas; Pancreatic Adenocarcinoma; Participant; Pathologic; Pathology; Patients; Physicians; Pilot Projects; Procedures; Protocols documentation; Research Project Grants; Resectable; Resected; Simulate; Site; Techniques; Technology; Testing; Tissues; Ultrasonography; United States National Institutes of Health; Universities; Validation; cancer therapy; chronic pancreatitis; clinical decision-making; clinical practice; computer science; data acquisition; design; improved; in vivo; innovation; mortality; pancreatic neoplasm; pre-clinical; programs; prospective; prototype; public health relevance; response; tool

DESCRIPTION (provided by applicant): Significance: Pancreatic cancer is the 4th deadliest form of cancer in the U.S., with 95% of patients dying within 5-years of diagnosis. Currently, such patients have limited treatment options due to the lack of reliable methods for early detection. A key challenge faced by clinicians is to differentiate those patients with chronic pancreatitis from those with cancer, as the clinical presentation is often indistinguishable. Early identification of the ~30% of pancreatic cancer patients who present with localized, potentially resectable disease would remove a critical barrier to progress in the field by enabling the rapid therapy essential for reducing mortality. Here, we will design, develop, and pilot test a robust new tool for clinical decision-making to improve the accuracy of cancer detection in the pancreas. Approach: We will develop innovative optoelectronic diagnostic technology that is compatible with commercial platforms for endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) to enable accurate diagnosis of pancreatic neoplasia in vivo. Our team represents a partnership between engineers and clinicians from the University of Michigan (U-M), most of whom have collaborated productively on the foundational (pre)-clinical optical studies in the pancreas, including a successful in vivo feasibility study, with physicians as key participants in all project aims. In Aim #1 we will design, build, and verify the endoscopy-compatible optoelectronic microprobe technology using design specifications identified from preliminary studies. In Aim #2 we will pilot test the technology in clinically-simulated environments, includin optical testing on human pancreatic tissues, per robust clinical data acquisition protocols we established previously. Impact: Currently, for almost all patients, pancreatic cancer is a lethal disease. The potential impact of this project on clinical practice for this targeted cancer problem is large: improved clinical outcomes via early and accurate detection of those pancreatic cancer patients most amenable to therapy and cure. Successful outcomes in this project might apply to other forms of cancer, as well.

描述（由申请人提供）：意义：胰腺癌是美国第四个最致命的癌症形式，其中95％的患者在诊断的5年内死亡。目前，由于缺乏可靠的早期检测方法，因此此类患者的治疗选择有限。临床医生面临的主要挑战是将慢性胰腺炎患者与癌症患者区分开来，因为临床表现通常是无法区分的。早期的 鉴定出约为30％的胰腺癌患者，这些患者患有局部，可切除的疾病，将通过降低死亡率必不可少的快速治疗来消除该领域进步的关键障碍。在这里，我们将设计，开发和试点测试一种强大的新工具，用于临床决策，以提高胰腺中癌症检测的准确性。方法：我们将开发创新的光电诊断技术，该技术与内窥镜超声引导的商业平台兼容，以实现体内胰腺肿瘤的准确诊断。我们的团队代表了密歇根大学（U-M）的工程师与临床医生之间的合作伙伴关系，其中大多数人在胰腺的基础（PRE）（PRE）（PRE）临床光学研究上进行了合作，包括成功的体内可行性研究，与医生作为所有项目的关键参与者的一项关键参与者。在AIM＃1中，我们将使用从初步研究中确定的设计规范设计，构建和验证与内窥镜兼容的光电微探针技术。在AIM＃2中，我们将根据我们先前建立的强大临床数据采集方案进行临床模拟环境中的技术测试，包括对人胰组织的光学测试。影响：目前，对于几乎所有患者，胰腺癌都是致命的疾病。该项目对这个目标癌症问题的临床实践的潜在影响 很大：通过早期和准确检测那些最适合治疗和治愈的胰腺癌患者，改善了临床结果。该项目的成功结果也可能适用于其他形式的癌症。